Skip to content

Management of Pain Associated With Failed Back Surgery Syndrome

Pregabalin Versus Gabapentin Efficacy in the Management of Neuropathic Pain Associated With Failed Back Surgery Syndrome

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05324761
Enrollment
60
Registered
2022-04-12
Start date
2022-04-25
Completion date
2022-06-30
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Failed Back Surgery Syndrome

Keywords

Pregabalin, Gabapentin, neuropathic pain, spine surgery

Brief summary

Neuropathic pain is a common complication following different types of spine surgery making negative impact on health, along with life style changes and management, many neurologist prescribed either Pregabalin or Gabapentin to manage this condition with overall good results. our study aims to evaluate the efficacy of Pregabalin and Gabapentin in the management of this condition and to compare between them

Interventions

Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.

Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.

Sponsors

Al-Kindy College of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Previous spine surgery and subsequent chronic back pain

Exclusion criteria

* Patients with connective tissue diseases * Patients with psychiatric illnesses

Design outcomes

Primary

MeasureTime frameDescription
Efficacy in Neuropathic pain managementoutcome will be assessed one month after the initiation of medicationVisual analogue scale pain, minimum score is 0, maximum is 10, the higher ther score the more severe pain

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026